Moderna, Inc. (NASDAQ:MRNA) announced significant advancements in its mRNA vaccine pipeline at its fifth Vaccines Day event, including successful clinical readouts for four vaccines targeting respiratory, latent, and other viruses. The company's diverse portfolio addresses major infectious diseases with 28 vaccines in development. Key updates include progress on vaccines for CMV, EBV, HSV-2, VZV, norovirus, COVID-19, RSV, and influenza. Moderna's CMV vaccine candidate, mRNA-1647, is in a pivotal Phase 3 trial, while its EBV vaccine candidates, mRNA-1189 and mRNA-1195, are advancing towards Phase 3 trials. The company also highlighted its ongoing Phase 3 trials for COVID-19, RSV, and flu vaccines, with mRNA-1345 for RSV showing promising efficacy. Moderna estimates the total addressable market for its infectious disease vaccines at $52 billion, with significant commercial opportunities in the coming years. The company's manufacturing innovation and investment in research and development support the commercialization of its pipeline.